AUS
NZ
UK
CA
USA
IND
Highlights
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) initiates a Phase 2a clinical trial for PTX-100 in cutaneous T-cell lymphoma.
The first study site has been established at Epworth Freemasons Haematology Clinical Trial Unit.
PTX-100 is a first-in-class inhibitor targeting the Ras pathway in cancer treatment.
Clinical Trial Expansion Prescient Therapeutics Ltd (ASX:PTX) has commenced a Phase 2a clinical study for PTX-100, a novel therapeutic candidate for cutaneous T-cell lymphoma (CTCL). The trial aims to evaluate the efficacy and safety of PTX-100 in patients with relapsed or refractory CTCL.
The company has launched its first study site at Epworth Freemasons Haematology Clinical Trial Unit in Melbourne. Professor Miles Prince, a recognized expert in CTCL treatment, serves as the principal investigator. Additional study sites are expected to open across Australia, the United States, and Europe in the coming months.
Study Design and Objectives The Phase 2a trial is structured as an open-label study, assessing two dosage levels of PTX-100. The primary endpoint focuses on efficacy, while secondary endpoints include safety and other clinical indicators. The study aims to enroll participants diagnosed with CTCL, a rare form of non-Hodgkin lymphoma affecting the skin.
Mechanism of PTX-100 PTX-100 functions as an inhibitor of geranylgeranyl transferase-1 (GGT-1), an enzyme involved in the Ras signaling pathway, which regulates cancer cell proliferation. By disrupting this pathway, PTX-100 promotes apoptosis in malignant cells.
The investigational therapy has previously demonstrated a favorable safety profile in earlier-stage clinical studies, including a Phase 1b expansion cohort. It is currently believed to be the only GGT-1 inhibitor in clinical development worldwide.
Regulatory Designation and Development Pathway The United States Food and Drug Administration (FDA) has granted PTX-100 Orphan Drug Designation for the treatment of all T-cell lymphomas. This designation provides regulatory incentives, including potential market exclusivity, to support the drug’s development.
The current trial will generate data to guide future research and clinical applications. Patient enrollment and initial dosing are set to commence soon.
Prescient’s Broader Oncology Pipeline PTX-100 is a key component of Prescient Therapeutics’ targeted therapy portfolio, which also includes innovative cell therapy platforms such as CellPryme-M, CellPryme-A, and OmniCAR. These platforms are designed to enhance cell therapy effectiveness, durability, and adaptability.
While the company’s cell therapy programs remain in preclinical stages, they are being developed to advance personalized cancer treatment options. The integration of PTX-100 into Prescient’s pipeline reflects its ongoing commitment to oncology research.
Upcoming Updates and Investor Briefing Prescient Therapeutics is hosting a live briefing on March 31 at 12 PM AEDT to discuss the PTX-100 program and broader research initiatives. Further updates on trial site activations and study progress are anticipated in the near future.
